Shares of PROCEPT BioRobotics (PRCT) tumbled 6.05% in after-hours trading on Tuesday, despite reporting better-than-expected third-quarter results. The surgical robotics company's forward-looking guidance appears to have disappointed investors, overshadowing its strong quarterly performance.

PROCEPT BioRobotics reported Q3 revenue of $83.327 million, surpassing the analyst estimate of $80.9 million. The company's adjusted EBITDA loss of $7.395 million was also better than the expected loss of $10.2 million. However, the focus shifted to the company's outlook for fiscal year 2026.

While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% growth over the previous year, its 2026 revenue guidance raised concerns. The company projects 2026 revenue to be in the range of $410 to $430 million, indicating a growth of 26% to 32% compared to the 2025 guidance. This growth rate, while still robust, marks a deceleration from the current year's expected growth, potentially explaining the negative after-hours reaction.